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Abstract 
 
 
Apurva Manohar Hegde, B.E.  
 
Advisor: Subrata Sen, Ph.D. 
 
 
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in 
the US. Among the many genomic aberrations previously implicated in 
colorectal cancer, recurrent amplification of chromosome 20q is frequently 
associated with liver metastasis. Previous research in our lab identified a 
gene signature on chromosome 20q associated with colorectal cancer 
progression. In this study, one of the genes in the signature, the ubiquitin 
conjugating enzyme UBE2C, was identified through preliminary bioinformatics 
analysis as a candidate for further examination of its role in CRC progression. 
Co-expression analysis of UBE2C in tumor-normal datasets from the public 
database Oncomine revealed all the datasets showing its highest co-
expression with Aurora kinase A (AURKA) pathway members, i.e. with 
AURKA and its binding co-factor and activator TPX2, all being localized on 
chromosome 20q. In addition, preliminary immunoblotting experiments in a 
panel of ten CRC cell lines showed high positive correlation between 
endogenous protein expression of UBE2C and AURKA. Overexpression of 
AURKA led to an increase in UBE2C protein as well as transcript levels, 
although UBE2C protein levels remained stable when cells were treated with 
Aurora kinase A inhibitor, suggesting that the mechanism of regulation is 
independent of the kinase activity. Furthermore, we found evidence of a novel 
interaction between AURKA and UBE2C protein by co-immunoprecipitation 
experiments. Finally, we assessed the impact of AURKA expression on the 
half-life of UBE2C protein using cycloheximide pule-chase assay. In 
summary, we report a novel relationship between two cell cycle proteins 
AURKA and UBE2C with potential implications for a new combination therapy 
in colon cancer. 
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Background and Introduction 
      Cancer is a group of diseases characterized by uncontrolled growth and 
spread of abnormal cells, with disruption of the genetic architecture of cells 
being one of the hallmarks of the disease. It has emerged as one of the most 
dreaded diseases known to mankind and poses a formidable challenge in the 
field of medicine. Cancer of the colon and rectum in particular, is estimated to 
cause 49,700 deaths in the United States in 2015, the third leading cause of 
cancer-related deaths for the two sexes separately, and the second leading 
cause when men and women are combined [Cancer Facts & Figures (2015), 
Link 1]. Despite increased screening for premalignant lesions contributing to 
decreased incidence of this disease over the past 20 years, the rate per 
100,000 still remains high in the US, with survival rate dropping from 90% in 
patients with localized disease to only 13% in patients with distant metastatic 
spread [Global Cancer Facts & Figures (2014), Link 2; Cancer Facts & 
Figures (2015)]. Therefore, elucidating the underlying mechanisms driving 
progression of this cancer is essential for developing effective biomarkers and 
therapeutic interventions.  
 
Colorectal Cancer pathogenesis 
      Figure 1 shows different pathways known to cause Colorectal Cancers 
(CRCs) [1].  
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Figure 1. Molecular pathways implicated in colorectal tumorigenesis. The 
chromosomal instability pathway characterized by sequential loss-of-function 
and gain-of-function aberrations in tumor suppressors and oncogenes 
respectively, was first discovered, followed by microsatellite instability 
pathway that affects DNA mismatch-repair genes. Recently, another pathway 
that is characterized by epigenetic changes to key mismatch repair genes has 
been discovered in a smaller set of patients.  
Reprinted by permission from Macmillan Publishers Ltd: American Journal of 
Gastroenterology (Ahnen, DJ;  2011; 106(2):190-8), copyright (2011).   
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CRCs are diverse in their underlying genetic makeup and are frequently 
characterized by genetic instability [2], arising due to microsatellite instability 
(MIN) and  chromosomal instability (CIN). These two pathways of CRC 
pathogenesis are thought to evolve independently. MSI tumors make up 
about 15% of all CRCs, harboring mutations, mismatched basepairs and/or 
indels in the repetitive microsatellite sequences present throughout the human 
genome [3]. These characteristic alterations in the microsatellite sequences 
have been shown to arise due to defects in DNA mismatch repair genes [4]. 
The rest of the ~85% of CRCs are characterized by CIN, which is reflected in 
persistent gain or loss of whole chromosomes or large portions of 
chromosomes [5].  
      Although whether CIN is the cause or consequence of tumorigenesis is 
still debated [6, 7], it is beyond doubt that CIN increases the likelihood of 
tumorigenesis and drives the progression of the disease. Multiple studies, 
including a meta-analysis of ~10,000 patients by Walther et al in 2008, have 
shown CIN to be significantly associated with a worse prognosis and survival 
in CRC patients [8-10]. Another study found CIN to confer intrinsic multidrug 
resistance to colorectal tumors [9]. Though the importance of CIN has been 
well studied in the context of various cancer types, the molecular mechanisms 
driving the genomic changes that are characteristic of CIN are not yet fully 
understood.  
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Chromosome 20q in CRC pathogenesis 
      One genomic aberration that is frequently seen in CIN tumors is gain of 
chromosome arm 20q. Chromosome 20q is one of the most frequently 
amplified genomic regions in colorectal tumors [11, 12] and is reported to 
occur early during tumorigenesis [13, 14]. In 2011, Tabach et al proposed a 
model of cancer initiation driven by spontaneous 20q amplification, describing 
the upregulation of expression of genes localized on 20q directly and 
indirectly altering the role of transcription factors as well as oncogenic 
signaling pathways, thus causing a change in various cellular functions 
including cell cycle activity, metabolic pathways and cell-adhesion.  This 
finding was confirmed by the large scale study undertaken by The Cancer 
Genome Atlas (TCGA) consortium, which identified chromosome 20q13.12 as 
one of the genomic hotspots associated with tumor aggressiveness [15].   
      Specifically, several studies have found amplifications on chromosome 
20q to be associated with liver metastasis [16-22], one of the predominant 
sites of metastasis in colorectal cancer [23] . In 2000, Hidaka et al showed 
that primary CRC tumors with liver metastasis are enriched for amplification in 
regions of chromosome 20q, with at least 89% of primary tumors with liver 
metastases and 94% of metastatic lesions showing gains on chromosome 
20q and the mean level of relative copy number correlating with tumor 
progression [19]. More recently, the application of newer technology to study 
chromosome 20q amplifications have confirmed these findings. In 2010, 
Sayague´s, J.M. et al utilized data from 500K SNP arrays to confirm that the 
genetic profile of metastatic CRC was defined by imbalanced gains of 
chromosomal regions that frequently included chromosome 20q [11]. In the 
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same year, Bruin S.C. et al described a novel classifier system named LM-
PAM predominantly based on chromosome 20q aberrations, to predict 
patients who were likely to develop liver metastasis with an accuracy rate of 
80% [17]. Evidence from such studies suggests that genes on chromosome 
20q likely drive the selection for the amplification of this region of the genome 
in more aggressive tumors. 
      Previous work in our lab identified a chromosome 20q gene signature 
associated with CRC progression [Carter, J. et al, unpublished data], by 
utilizing two in vitro colorectal cancer model systems – the SW (SW480 and 
SW620) and KM12 (KM12C, KM12SM and KM12L4C) series cell lines. The 
cell line SW480 was derived from the primary colon tumor of a Duke’s Stage 
B CRC patient whereas SW680 is the lymph-node derivative of the same 
patient with recurrent metastatic disease [24]. In contrast, the highly 
metastatic KM12SM and KM12L4C cell lines were established from tumors 
growing in nude mice that had been implanted with KM12C cells, the poorly 
metastatic parental line derived from a Duke’s Stage B colorectal tumor, into 
the spleen of nude mice or injecting subcutaneously into their cecum [25]. 
Integrated copy number and mRNA expression analysis of the five cell lines 
led to the identification of a 4-gene signature localized on the three Minimal 
Common Regions (MCRs) of amplification on chromosome 20q, suggesting 
that these amplified genomic regions containing the gene signature are 
selected for during the metastatic process.  
      The gene signature consists of 4 genes, namely BMP7, DNMT3B, UBE2C 
and YWHAB, all of which have been previously implicated in cancer [26-34]. 
Moreover, when the gene signature was analyzed in a large cohort of patients 
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from The Cancer Genome Atlas Colorectal Cancer study, the expression 
profile of the gene signature was found to show significant association with 
negative prognostic characteristics like lymph node spread and/or distant 
metastasis, as well as CIN expression subtype, suggesting that gain of 
function alterations in the gene signature may contribute to disease 
progression.  
 
Investigation of candidate gene for further examination 
      The rationale behind this study was to narrow down on one candidate 
gene from the signature whose functional impact on the progression of CRC 
could be studied at a molecular level. We used two filtering criteria to prioritize 
the genes of the 20q signature for further examination. The first criteria 
included the results of a recent study by Zhang et al in 2014, characterizing 
the proteogenomic profile of the colorectal sample cohort from the TCGA 
dataset. This was the first large scale study to integrate the genotype and 
phenotype information based on proteomic and genomic profiles in CRCs 
[35]. In this study, the proteomic analysis of 95 CRC samples, performed 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and 
covering a total of 7,211 genes, was compared to the corresponding genomic 
aberrations as well as RNA-seq information reported in the original CRC 
samples analyzed by TCGA. The findings show that chromosome 20q gain is 
associated with the largest global mRNA and protein level changes in CRC. 
89% of the 79 genes that had quantifiable protein measurements showed 
significant Copy Number Alteration (CNA)-mRNA correlation, but only 51% 
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showed significant CNA-protein correlation (P<0.01), suggesting that these 
genes may be preferentially selected for during the tumorigenic process. In 
particular, of the four genes in the gene signature, it was interesting to note 
that UBE2C and YWHAB showed significant CNA-mRNA as well as CNA-
protein correlation, indicating that these genes may have a direct functional 
impact on tumorigenesis. It must be noted that the other two genes in the 
signature – BMP7 and DNMT3B, did not have quantifiable protein 
measurements that could be utilized for this analysis. Nevertheless, this 
finding helped narrow down from four to two candidate genes for further 
examination in our study. 
      Secondly, we wanted to examine if the candidate genes revealed a 
pattern of co-expression with previously well-characterized oncogenes. We 
performed co-expression analysis in silico using the public database 
Oncomine on ten colorectal tumor datasets where we examined genes that 
co-expressed with UBE2C and YWHAB. While YWHAB did not show a 
discernible pattern of significant co-expression with any particular cancer-
related signaling pathway across the datasets, UBE2C was highly co-
expressed with the Aurora A Kinase (AURKA) pathway members, i.e. AURKA 
and its binding and activating co-factor TPX2, in ten out of ten datasets, 
suggesting a pattern of co-expression of UBE2C with known cancer driver 
genes. A representative result is in Figure 2, data used from Tsukamoto et al, 
2011[36].  
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Figure 2. Co-expression analysis of mRNA expression data from Oncomine.  
Example dataset shown is from Tsukamoto et al, Clin Cancer Research 
(2011) [36]. Correlation of expression of UBE2C and AURKA at the mRNA 
level is evident across the normal samples and different tumor types, with the 
expression increasing in carcinomas, compared to adenomas and normal 
samples. 
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Similarly, when we analyzed the mutual co-occurrence of overexpression of 
UBE2C and YWHAB with AURKA in the TCGA CRC cohort, UBE2C and 
AURKA revealed a higher mutual co-occurrence rate as compared to YWHAB 
and AURKA (Figure 3). This further confirmed the co-expression analysis 
results from Oncomine. 
 
  
 
 
 
 
 
 
 
                                                             
                                                            
Figure 3. Mutual exclusivity analysis from cBioPortal website. Overexpression 
of UBE2C and AURKA shows a stronger tendency of co-occurrence at the 
mRNA level as compared to that between AURKA and YWHAB. Analysis was 
performed using TCGA Colorectal Cancer study samples (as of August 2014). 
Legend is provided for the color scheme represented.   
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      Since the Oncomine co-expression analysis was performed using mRNA 
expression data, we wanted to validate these findings at the protein level. A 
preliminary examination of endogenous protein levels of AURKA and UBE2C 
by western blotting in ten exponentially growing colorectal cancer cell lines 
revealed that six of the ten cell lines showed a positive correlation between 
AURKA and UBE2C protein expression, whereas we did not see any 
correlation between AURKA and YWHAB, as the expression of YWHAB was 
unchanged in all cell lines.  
      Given that AURKA and TPX2 have been previously reported to promote 
20q-amplicon-driven colorectal adenoma to carcinoma progression [37], it 
was interesting to note that UBE2C expression was positively correlated with 
AURKA pathway members at the mRNA and protein levels, suggesting a 
possible co-operation between the signaling axes in driving tumorigenesis, 
thus prompting us to further focus on the possible interaction between the 
two, to investigate their potential impact on CRC pathogenesis. 
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Hypothesis and aims of the project 
 
      Based on the aforementioned observations, the central hypothesis of this 
project is that functional interaction between AURKA and UBE2C contributes 
to colorectal carcinogenesis.  
      To test this hypothesis, I propose the following specific aims  
1) AIM 1: To determine the effect of change in AURKA protein 
expression and activity on UBE2C protein levels 
2) AIM 2: To examine the effect of change in AURKA expression on 
the transcriptional regulation of UBE2C expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Methods 
Cell lines and tissue culture 
      A total of ten cell lines were used in this study. Caco-2, SW480, SW620, 
HT-29, HCT116, RKO and DLD-1 were procured from American Type Culture 
Collection (ATCC). The KM12 series of cell lines were a gift from Dr Isaiah 
Fidler’s laboratory at UT MD Anderson Cancer Center. Caco-2, HCT116 and 
RKO cell lines were cultured in MEM media, HT-29 in McCoy’s media, DLD-1 
in RPMI-1640 and SW series of cell lines in DMEM/high glucose media, all 
with 10% FBS (15% FBS for Caco-2), 1% L-glutamine and 1% 
Penicillin/Streptomycin (Corning, 25-005-Cl and 30-002-Cl respectively); 
KM12 series of cell lines were cultured in MEM media with 1mM sodium 
pyruvate (Sigma-Aldrich, S8636), 1ml of NEAA per 100ml of media (Lonza, 
13-114E), 1% L-glutamine and 1% Penicillin/Streptomycin. All cells were 
cultured in a CO2 incubator with 5% CO2 at 37oC.  
 
Transfection of DNA, siRNA and Protein isolation      
5ug plasmid DNA and 80nm SiRNA were transfected into cells in serum free 
media at 70-80% confluence using OPTIMEM reduced serum reagent (Life 
technologies Inc) and Lipofectamine 2000 (Life Technologies Inc.) 
transfection reagent, according to manufacturer’s recommendation, for 24 to 
72 hours. Media was changed to normal growth media 6 hours after 
transfection. SiRNA targeting AURKA (custom SiRNA sequence 
AUGCCCUGUCUUACUGUCA) and UBE2C (SMARTpool ON-TARGET plus, 
catalog no. LU-004693-00-0005) were procured from GE Dharmacon. To 
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isolate protein, cells were washed twice with 100% PBS and lysed with 0.1L 
buffer (for 50ml buffer: 0.02M Tris HCl (pH 8.0), 0.1M NaCl, 500uM EDTA, 
0.05M NaF, 1% NP40, Protease inhibitor (Roche) – 1 tablet, make up the 
volume to 50ml with ddH20) for co-IP and RIPA buffer (for 50ml buffer: 0.02M 
Tris-HCl, 0.15M NaCl, 1uM EDTA, 1% Triton X-100, 0.5% Sodium 
Deoxycholate, 0.1% SDS, protease inhibitor – 1 tablet, make up the volume to 
50ml with ddH20). Protein concentration was measured using Bradford 
reagent (Bio-Rad) according to manufacturer’s protocol.  
 
Drug treatments 
      Alisertib (MLN8237) was dissolved in 100% DMSO and was used at 
100nM and 500nM concentration for 1 hour and 24 hours.  Corresponding 
volumes of 0.05% DMSO treatment was used as negative control. Total 
protein was isolated from lysed cells as described above. For co-IP 
experiments with cells arrested in mitosis, nocodazole treatment was 
performed at 2.5ug/ml concentration for 16 hours. 
 
Quantitative Real Time PCR 
      Total RNA was isolated from transfected cells using TRIzol reagent 
(Invitrogen) and phenol-chloroform precipitation according to manufacturer’s 
recommendation. Extracted RNA was treated with DNase I (Life technologies) 
to remove DNA contamination. 2-3 ug DNase-treated RNA was converted to 
cDNA using Superscript II RT kit (Life Technologies) according to 
manufacturer’s recommended protocol. Primer sequences are: AURKA Fwd - 
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5’-GCCCTGTCTTACTGTCATTCG-3”, Rev – 5’-
ACAGAGAGTGGTCCTCCTGG-3’,  UBE2C Fwd – 5’-
GGACCATTCTGCTCTCCATCC-3’, Rev – 5’- AGCTGTGGGGTTTTTCCAG -
3’. mRNA levels were quantified using SYBR green qPCR master mix (Life 
technologies, catalog no. 4309155) and fluorescent signal was measured by a 
ViiA 7 Real-Time PCR System (Life technologies).  Target specificity was 
confirmed by melting curve analysis. Relative gene expression fold change 
values were calculated using the 2-ΔΔCTmethod as outlined in Link 3. Variance 
in the normalized RT-PCR values was calculated using the F-test and 
statistical significance was calculated using the Student’s t-test. Graphs were 
created using Graphpad prism. 
 
Co-immunoprecipitation 
      1mg of protein was pre-cleared by incubation with protein-A agarose 
beads while rotating for 1 hour at 4oC. The supernatant was incubated with 
primary antibody overnight at 4oC. The antibody-protein lysate mixture was 
then incubated with fresh protein-A agarose beads and the unbound 
supernatant was discarded. The beads were denatured using SDS and heat 
denaturation by boiling for 5 minutes. These samples were then used to 
perform SDS PAGE followed by western blotting as described below. 
 
Cycloheximide assay 
Cells were cultured in 10 cm dishes and transfected either with Flag-tagged 
AURKA and empty vectors for a period of 24 hours, or siAURKA and 
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scrambled siRNA for 48 hours, using lipofectamine2000 transfection reagent, 
using manufacturer’s protocol. Cycloheximide reagent at a concentration of 
50ug/ml was added to the cells and cells were harvested with RIPA at various 
time points. Immunoblotting was carried out after protein isolation and 
quantification as described above and below.   
 
Immunoblotting 
      Cell lysates or co-IP samples as stated above, were denatured using 1X 
SDS and by boiling at 100oC for 5 minutes. Denatured cell lysates were run 
on either 10% or 12% polyacrylamide gels, transferred to nitrocellulose 
membrane, and incubated with primary antibody (List of primary and 
secondary antibodies in Table 1) on a shaker at 4oC, overnight. 
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Table 1. List of antibodies used in western blotting. 
 
 
 
 
 
 
 
Antibody Company (Catalog no). 
IAK BD (610939) 
BTAK/STK15 [38] 
UBE2C (full length) Abcam (ab56861) 
UBE2C (N-terminal) Abgent (AP2119a) 
UBE2C (C-terminal) Abgent (AP2119b) 
Phospho-AURK A/B/C CST (29146) 
TPX2 
Bethyl laboratories (A310-
101A) 
YWHAB Santa Cruz (SC-629) 
BMP-7 Sant Cruz (SC-9305) 
ID1 Santa Cruz (SC-488) 
Flag Sigma (F1804) 
Cleaved PARP CST (9541S) 
Cleaved Caspase CST (9661) 
HSP90 Santa Cruz (SC-13119) 
ACTB Santa Cruz (47778) 
Anti-HRP (Rabbit IgG) Genedepot (W3902-500) 
Anti-HRP (Mouse IgG) GE Healthcare (NXA931) 
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Results 
 
AURKA and UBE2C protein expression are positively correlated in colon 
cancer cells 
      In order to validate the results of the Oncomine co-expression analysis as 
well as our findings from the TCGA mutual-co-occurrence analysis in 
colorectal cancer, we examined the endogenous protein levels of AURKA and 
UBE2C in ten cell lines by western blotting. These were seven MSS cell lines 
including Caco2, SW480, SW620, KM12C, KM12SM, KM12L4A, HT-29 and 
three MSI cell lines including HCT116, RKO and DLD-1. We observed a 
positive correlation between AURKA and UBE2C in six of the ten cell lines 
(Figure 4). Those cell lines that showed higher endogenous AURKA protein 
levels also showed high UBE2C expression, cell lines with moderate AURKA 
expression revealed relatively lower UBE2C levels whereas the cell lines that 
expressed very little AURKA protein showed the lowest UBE2C levels. In 
addition, we observed a similar phenomenon with the expression of TPX2, the 
binding and activating partner of AURKA, showing positive correlation with 
AURKA and UBE2C. We also examined the expression levels of ID1 and 
BMP-7 which are localized on chromosome 20q, to confirm that the 
correlation did not stem due to potential amplification of chromosome 20q, 
and did not see a correlation of their expression with AURKA. 
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Figure 4. Endogenous expression of UBE2C, AURKA, phospho-AURKA and 
additional chromosome 20q encoded proteins (YWHAB, TPX2, ID1, BMP-7). 
Cell lines that show highest AURKA expression also show high expression of 
UBE2C whereas cell lines with low AURKA expression also express UBE2C 
at very low levels. Loading control used is HSP90. 
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AURKA overexpression leads to increase in UBE2C protein levels  
      We were interested in examining whether change in AURKA expression 
would effect a change in UBE2C levels too. Three cell lines were chosen for 
further examination based on their endogenous expression levels of AURKA 
and UBE2C, their comparable doubling time as well as transfection efficiency, 
with one cell line, SW480, being consistently used in all experiments. 
Overexpression of Flag-tagged AURKA by transient transfection led to an 
increase of UBE2C protein levels as compared to empty vector controls in all 
three cell lines, indicating a positive correlation between the expression levels 
of the two proteins (Figure 5). As can be seen from the figure, we confirmed 
transfection efficiency by checking the intensity of the Flag epitope in the 
expressed Flag-tagged AURKA protein. 
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Figure 5. Protein expression of UBE2C when Flag-tagged AURKA plasmids 
are transiently transfected into SW480, KM12C and HT-29 cells, as 
determined by immunoblotting. Expression of UBE2C increases when AURKA 
is overexpressed.  
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AURKA knockdown down-regulates UBE2C expression at the protein 
level 
      We wanted to confirm the above findings to see whether UBE2C levels 
decrease upon knockdown of AURKA expression. We treated three cell lines, 
SW480, KM12C and HT-29, with siRNA targeting AURKA and probed for 
UBE2C protein using western blotting. siRNA sequences for AURKA are 
provided in the Methods section. We observed a corresponding decrease in 
UBE2C expression when AURKA expression was down-regulated, confirming 
the above observation that a positive correlation exists between AURKA and 
UBE2C in colon cancer cells (Figure 6) and suggesting that AURKA regulates 
UBE2C expression either transcriptionally or post-translationally. 
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Figure 6. Protein expression of UBE2C when AURKA is knocked down by 
siRNA treatment in SW480, KM12C and HT-29 cells, as determined by 
immunoblotting. Expression of UBE2C also decreases when AURKA levels 
are diminished. 
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Positive correlation between AURKA and UBE2C expression is reflected 
at the mRNA level 
      We were curious to see whether the above phenomenon was limited to 
the protein level, thus indicating a solely post-translational mechanism of 
regulation of UBE2C expression, or whether it was also reflected at the 
transcript levels. We overexpressed Flag-tagged AURKA in SW480 and 
KM12C cell lines and checked for the expression of AURKA and UBE2C 
mRNAs using quantitative RT-PCR. Primer sequences for the PCR assay can 
be found in the Methods section. We observed a statistically significant 
increase in the expression of UBE2C mRNA in the presence of higher 
expression of AURKA (Figure 7).  
 
Figure 7. mRNA expression of UBE2C when Flag-tagged AURKA is 
overexpressed, as determined by quantitative RT-PCR (* p<0.01, ** p=0.02). 
Overexpression of AURKA leads to a moderate increase in UBE2C levels. 
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      We further wanted to confirm these results by investigating the effect of 
knockdown of AURKA on UBE2C mRNA levels. RNAi-mediated down-
regulation of AURKA led to a statistically significant decrease in UBE2C 
transcript levels, as seen in Figure 8.  
Figure 8. mRNA expression of UBE2C when AURKA is knocked down by 
siRNA treatment, as determined by quantitative RT-PCR (* p<0.01, *** 
p<0.05). Knock-down of AURKA leads to a moderate decrease of UBE2C. 
       
The above results suggested the possibility that AURKA may be 
involved in transcriptional regulation of UBE2C expression. Searching for 
potential DNA-binding or transactivation sites in the AURKA protein sequence 
using multiple prediction softwares did not yield any predicted sites. We were 
also curious to see whether known targets of AURKA may be acting as 
potential transcription factors and helping regulate UBE2C levels. However, 
potential transcription factor binding sites in the UBE2C promoter region from 
ENCODE did not reveal any known  AURKA downstream targets in the list of 
most relevant predicted transcription factor binding sites (Link 4). The 
findings, nonetheless, raise the interesting possibility that transcription 
factor(s) regulating UBE2C expression may be substrate(s) of AURKA, which 
remain to be identified. Besides, AURKA appears to be regulating UBE2C 
protein expression at the translational level.  
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Regulation of UBE2C expression is independent of AURKA kinase 
activity 
      Since Aurora A functions primarily as a serine/threonine kinase, we 
wanted to examine the change in UBE2C expression when kinase activity of 
AURKA was inhibited using the drug Alisertib (MLN8237). We treated the cell 
lines SW480 and KM12C with increasing doses of the drug, each for 1 hour 
and 24 hour durations, inducing the repression of phospho-AURKA 
expression. As seen in Figure 9, we did not see a change in UBE2C levels 
between treated and untreated controls at 100nM concentration of the drug, 
though at the 500nM concentration of Alisertib treatment, we did see a 
decrease in the protein levels of UBE2C. However, at this concentration we 
also saw decrease in activated AURKB and AURKC. Since it is known that 
Alisertib shows >200 fold higher selectivity for AURKA over the other Aurora 
kinases [39], it leads us to believe that the change in UBE2C may be due to 
off-target effects of the drug and may not truly reflect the change caused by 
inhibition of AURKA alone.  
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Figure 9. Protein expression of UBE2C after treatment of SW480 (a) and 
KM12C (b) cell lines with AURKA inhibitor Alisertib, as determined by 
immunoblotting. Decrease of activated AURKA does not show significant 
change in UBE2C protein expression.  
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Co-immunoprecipitation shows evidence of binding between UBE2C 
and AURKA 
      Keeping in view the recent study showing kinase-independent regulatory 
function of AURKA in neuroblastoma cells [40], we sought to examine 
whether AURKA may be binding to UBE2C in the cell and thus playing a role 
in increasing its expression. On performing co-immunoprecipitation of AURKA 
and UBE2C in exponentially growing SW480 and KM12C cells, we observed 
UBE2C binding to AURKA (Figure 10 a). Interestingly, in both cell lines we 
were able to visualize the binding only when UBE2C antibody was used for 
immunoprecipitation and AURKA was probed in the immunecomplex by 
immunoblotting. However, we failed to detect UBE2C protein in immune-
complex precipitated with AURKA antibody. .  
AURKA is a mitosis regulatory enzyme that peaks expression during G2-M 
phase of mitosis. In order to rule out the possibility that low expression of 
AURKA in exponentially growing cells limits its availability for binding with 
UBE2C, we treated SW480 cells with nocodazole, which is an anti-neoplastic 
agent that arrests cells in mitosis by inhibiting microtubule polymerization. 
This time, we did detect UBE2C binding to immunoprecipitated AURKA, 
although the interaction was weak (Figure 10 b).  
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a. 
 
 
 
b. 
 
 
Figure 10. Co-immunoprecipitation of AURKA and UBE2C in a) exponentially 
growing SW480 and KM12C cells and b) Nocodazole treated SW480 cells. 
AURKA binding is visible in samples where UBE2C has been 
immunoprecipitated and probed for the presence of AURKA.  
 
 
29 
 
UBE2C protein levels are stabilized by AURKA expression       
      As shown above, the results of the AURKA-overexpression and 
knockdown studies indicated a correlation in the expression of AURKA and 
UBE2C. In addition, we also found AURKA binding to UBE2C, suggesting the 
possibility that AURKA may be involved in stabilization of UBE2C levels in the 
cell. We performed cycloheximide pulse-chase assay to determine the effect 
of change in AURKA expression on half-life of UBE2C. Cycloheximide 
treatment was performed on SW480 cells that had undergone AURKA 
overexpression for 24 hours as compared to empty vector controls, following 
which cells were harvested at various time points to examine the levels of 
protein expression. Conversely, we also studied cells in which AURKA had 
been knocked down for 48 hours using RNAi and compared them to cells 
expressing scrambled Si controls for protein expression levels in the presence 
of cycloheximide. 
      In the first case, we found that UBE2C as well as AURKA expression in 
empty-vector treated cells was diminished at the 4 hour time point , whereas 
cells that showed overexpression of AURKA also showed higher expression 
of UBE2C at this time interval, with expression returning to basal  levels  after 
decrease in AURKA expression at 10 hours (Figure 11 a). In contrast, in cells 
where AURKA had been knocked down using siRNA, UBE2C levels 
diminished at the 6 hour time point, whereas scrambled Si transfected cells 
showing higher AURKA levels did not show diminished UBE2C expression, 
although its expression did change in correlation with that of AURKA (Figure 
11 b). These results indicate that AURKA protein level is involved in regulating 
the protein half-life of UBE2C.              
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 a. 
 
b. 
 
Figure 11. AURKA and UBE2C expression as determined by densitometry-
based quantification of immunoblot signals performed after cycloheximide 
pulse-chase assay in SW480 cells. Higher AURKA expression shows higher 
levels of UBE2C for longer intervals of time.   
SW480 
SW480 
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Summary and Discussion 
      The focus of this work was to explore a possible novel interaction between 
cell cycle enzymes Aurora A Kinase (AURKA) and ubiquitin conjugating 
enzyme E2C (UBE2C) in colon cancer cells, both  encoded on chromosome 
20q and displaying similar elevated expression profiles in large colon cancer 
sample cohorts reported in publicly available datasets, such as, Oncomine 
and TCGA. . Implication of chromosome 20q amplification in colorectal cancer 
progression has been well documented, but attempts at narrowing down the 
genes that drive the selection for this amplification seen in CRCs, especially in 
tumors that metastasize to the liver have so far been limited. The significance 
of this study lies in the possibility that disruption of this plausible interaction 
may help in developing new therapeutic strategies for CRC patients who 
overexpress these proteins.  
      The Aurora kinase gene was first discovered in Drosophila melanogaster 
as being responsible for the formation of defective, monopolar spindles when 
mutated [41]. Since then, three homologous proteins of the kinase family have 
been discovered in humans – Aurora A, B and C kinases (AURKA, AURKB, 
AURKC). AURKA has been well studied as a cell cycle enzyme that 
predominantly localizes at the centrosomes during mitosis and at the spindle 
poles through to the M phase of the cell cycle, regulating important functions 
like centrosome maturation, microtubule formation and spindle assembly [42].  
      The association of AURKA with cancer was first reported two years after 
the gene was discovered. In 1997, Sen et al was the first group to report 
AURKA (BTAK) as amplified and overexpressed in breast cancer cells [43]. 
Since then elevated levels of AURKA have been reported in multiple cancers, 
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including almost 94% of invasive ductal carcinoma of the breast showing 
enhanced expression of AURKA [43] and it’s overexpression was shown to 
cause tumorigenic transformation both in vitro and in vivo [38, 44].          
      Chromosome 20q13.2, the region that AURKA maps to, is a known 
hotspot for amplification in many human cancers. Owing to its function as a 
cell cycle regulatory protein, amplification and overexpression of AURKA has 
important implications for deregulation of normal cellular growth. Elevated 
levels of AURKA aid in overriding the spindle checkpoint that is activated 
when cells are treated with chemotherapeutic agents causing defective 
spindle assembly as well as microtubule destabilization [45, 46]. Moreover, 
AURKA overexpression leads to centrosome amplification resulting in 
defective chromosome segregation and failure of cytokinesis, thus giving rise 
to aneuploidy [38] and contributing to carcinogenesis.  
      Other molecular mechanisms through which AURKA contributes to 
disease progression have also come to light. In 2004, Katayama et al reported 
that increased AURKA expression leads to the phosphorylation and 
subsequent Mdm2-mediated degradation of p53, thus shutting down an 
important tumor suppressive pathway in cancer cells [47]. In the same year, it 
was also reported that AURKA-mediated phosphorylation of p53 at Ser215 
abrogates p53’s DNA-binding and transactivation functions, thus leading to 
downregulation of the downstream tumor suppressor transcriptional targets of 
p53 like p21 and PTEN [48]. In addition to the degradation of p53, AURKA 
also circumvents the p53-mediated apoptotic pathway by the suppression of 
p73 [49, 50].  
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      Given these important findings suggesting involvement of AURKA in 
carcinogenesis, it is apparent that AURKA is a potential therapeutic target for 
cancer. Different AURKA inhibitors have been developed, including MLN8054, 
which was terminated in phase I clinical trials as off target toxicities were 
reported [51]. More selective second generation drug MLN8237 (Alisertib), 
has shown improved efficacy in causing tumor regression by induction of 
senescence on the one hand and activation of apoptotic pathways on the 
other [52, 53] .  It is currently in clinical trials for some solid tumors both as a 
single agent as well as in combination with other drugs; however in recent 
clinical trials in gastrointestinal tumors, a small percentage of patients have 
shown a partial response to the drug [54]. Stratification of patients based on 
other biomarkers and combination therapy of AURKA inhibitors with other 
therapies is expected to yield better response among patients. 
      The ubiquitin conjugating enzyme E2C (UBE2C) gene was first cloned by 
Townsley et al in 1997, as a human homolog of the E2C ubiquitin carrier 
protein found in yeast [55]. The UBE2C gene is located on chromosome 
20q13.12 and is reported to have seven transcript variants generated through 
alternative splicing. UBE2C forms an important component of a large multi-
subunit ubiquitin ligase complex called the Anaphase Promoting 
Complex/Cyclosome (APC/C), which is required to ensure timely degradation 
of cell cycle molecules like Securin and Cyclin B1 in order for the cell to 
transition from metaphase to anaphase [56]. Specifically, it is involved in the 
initiation of mono- and poly-ubiquitination of APC/C targets within the cell [57, 
58]. It further promotes the ubiquitination of mitotic checkpoint proteins, 
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therefore helping in the inactivation of the spindle checkpoint allowing 
chromosome segregation to occur [59].  
      Perhaps due to its important functions in cell cycle progression, elevated 
levels of UBE2C have been observed in various cancers, including colon, 
liver, bladder, lung, gastric, breast, ovarian, etc. [60-63]. Its high expression 
has been associated with poor survival in lung cancer, high risk breast cancer 
patients, ovarian cancer, etc. [64-67]. In vitro, UBE2C overexpression was 
shown to impair mitotic arrest in cancer cells in the presence of spindle 
damaging agents like nocodazole [68], while in vivo, overexpression of 
UBE2C led to chromosome missegregation and aneuploidy due to increased 
APC/C activity [31]. It had also been shown earlier that when primary oral 
Squamous Cell Carcinomas (SCCs) were immortalized in culture, there was a 
dramatic increase in UBE2C protein levels [69], suggesting that UBE2C 
overexpression may play a role in evasion of senescence and increased cell 
proliferation.  
      More recently, in 2011, Bavi et al demonstrated that RNAi-mediated 
knockdown of UBE2C in colon cancer cells led to a decrease in cell growth 
[70]. They also observed downregulation of UBE2C on treatment with 
proteasome inhibitor Bortezomib, which further sensitized the cells to 
Bortezomib- and oxaliplatin-mediated apoptosis, implying that inhibition of 
UBE2C leads to suppression of cell growth in vitro. This was confirmed using 
xenograft models where Bortezomib-mediated downregulation of UBE2C led 
to increased shrinkage in tumor volumes in mice treated with Bortezomib and 
Oxaliplatin combination therapy. These observations suggest UBE2C to be a 
promising potential therapeutic target in colon cancer. 
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      In view of the above observations, our data point towards an interesting 
possibility of a yet unknown novel functional interaction between AURKA and 
UBE2C proteins that are known oncogenes. The mRNA data from TCGA and 
Oncomine revealing that overexpression of AURKA and UBE2C are closely 
tied was confirmed by our observation of a similar phenomenon at the protein 
level in exponentially growing CRC cells. The absence of correlation of 
expression of other 20q genes indicates that this phenomenon may not solely 
be due to overall 20q gain but more selective to AURKA and UBE2C. 
Interestingly, we found that UBE2C expression level is upregulated with 
increase in AURKA levels and is downregulated when AURKA is knocked 
down, both at the protein as well as mRNA levels. This reveals the possibility 
of a novel signaling axis that may be promoting disease progression in a 
subset of CRC patients who show overexpression of the two genes. 
        The absence of predicted DNA-binding and transactivation sites on 
AURKA as well as transcription-factor binding sites on UBE2C, coupled with 
the limited increase in UBE2C transcript levels even after 25 to 140-fold 
increase in AURKA levels indicates that perhaps a more potent post-
translational mechanism of regulation of UBE2C may be occurring in the cells.  
In this context, the 2009 study by Otto et al, that found AURKA to stabilize N-
MYC in a kinase-independent manner in neuroblastoma cells by binding to it 
and protecting it from proteasome-mediated degradation becomes relevant 
[40]. Our observation that UBE2C levels remain constant in spite of AURKA 
inhibition by the drug Alisertib led us to investigate a potential kinase-
independent mechanism of AURKA-mediated UBE2C regulation. 
Interestingly, in the co-IP studies, we found AURKA binding after 
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imunoprecipitating UBE2C from the cell extracts, although failed to detect 
UBE2C in the immune complex when we pulled down with AURKA antibody 
in both the cell lines. The absence or very low binding of UBE2C detected in 
the immune complexes pulled down with AURKA antibody even after 
treatment with a mitotic-arrest agent implies that this phenomenon may not be 
dependent on the level of expression of AURKA, since AURKA shows highest 
expression during mitosis. This may indicate the possibility of preferential 
binding of AURKA with other proteins in the cell or the IP antibody competing 
with UBE2C to bind to AURKA, which warrants further experiments with 
antibodies against various different epitopes on AURKA protein.  
      Further, the evidence of binding between the two proteins prompted us to 
examine whether AURKA may play a role in stabilizing UBE2C levels in the 
cell. Cycloheximide assay shows higher levels of UBE2C when AURKA is 
expressed in high amounts, with both AURKA and UBE2C expression 
decreasing coordinately after several hours of cycloheximide treatment, 
indicating protein degradation. In both the samples, protein expression 
decreased in parallel at the 4 hour time point but rose again, suggesting that 
the cycloheximide may have been metabolized by the cells by this time point. 
The overall higher amounts of UBE2C in the scrambled Si-treated cells shows 
that it would take longer for it to be degraded in the presence of AURKA 
expression as compared to when AURKA levels are knocked down. Taken 
together, these studies are suggestive of the positive impact of AURKA 
signaling on the expression of UBE2C. However, it would have to be further 
determined whether AURKA regulates UBE2C stabilization directly by binding 
 
 
37 
 
to it, by repeating these experiments using deletion and mutation constructs of 
UBE2C and AURKA.       
      In addition, the novel relationship between UBE2C and AURKA 
highlighted in this study has the potential to impact different cellular processes 
regulated by UBE2C. As mentioned earlier, UBE2C is involved in the initiation 
of mono- and poly-ubiquitination of APC/Cyclosome targets within the cell. 
While mono-ubiquitination has been reported to play a role in different 
processes, including epigenetic regulation of gene expression as well as 
modification of proteins that regulate DNA repair pathways, poly-ubiquitination 
is generally employed by the cell to target proteins for proteasomal 
degradation [71-74]. Overexpression of UBE2C has been reported to cause 
cancer cells to enter mitosis even in the presence of spindle damaging agents 
like nocodazole [59]. AURKA-mediated overexpression of UBE2C could 
potentially have an additive effect on the oncogenic characteristics displayed 
when AURKA is overexpressed, by facilitating the deregulation of additional 
cellular processes that may be tumor suppressive in nature. This augmented 
effect could result in cancer cells exhibiting additional hallmarks of cancer, 
thus resulting in more aggressive tumors. Further work to delineate the effects 
of AURKA-mediated UBE2C overexpression on potential change in 
ubiquitination of its downstream targets will lay the foundation for discerning 
whether these changes impact the progression of disease.  
      In summary, we have successfully uncovered a novel interaction occurring 
between the cell cycle enzymes AURKA and UBE2C in colorectal cancer 
cells. We have confirmed the correlation of expression of the two proteins as 
well as potential regulation of UBE2C by AURKA that may have important 
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implications in promoting the aggressiveness of colorectal cancers, in view 
the well-characterized oncogenic properties of the proteins. Further 
investigation on the effects of abrogation of this interaction as well as 
elucidation of other signaling pathways possibly being affected by this 
interaction will help determine the importance of therapeutically targeting this 
novel signaling axis in CRC patients overexpressing the two proteins. 
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Future directions 
      The demonstrated interaction between AURKA and UBE2C has not been 
reported by earlier studies, and therefore has immense potential to be studied 
in the context of cancer pathogenesis and aggressiveness of the disease.. 
      The 2009 study by Otto et al elucidating the kinase-independent function 
of AURKA in stabilization of N-Myc by binding to it has expanded the diverse 
role that AURKA plays in promoting tumorigenesis. Since we have seen the 
indication of a similar phenomenon in our studies, it would be helpful to 
determine the binding motifs of the two proteins, using first deletion 
constructs, then followed by mutation constructs of UBE2C and AURKA to 
narrow down on the exact residues involved in this interaction. This will further 
help us determine whether binding of the two proteins is crucial in determining 
the half-life of UBE2C in the cell or whether increase in UBE2C half-life is 
merely the result of activation of AURKA downstream signaling pathway.  
      The functional impact of the interaction of AURKA and UBE2C on CRC 
cells needs to be elucidated. Important cellular functions deregulated in 
cancer, like invasive and migratory capacity of cells, could be examined by 
wound healing assays as well as other migration-invasion assays using stably 
generated cell lines that overexpress both AURKA as well as UBE2C as 
compared to cell lines overexpressing UBE2C but low level of AURKA. 
Determination of the impact of this signaling axis on the ability of anchorage-
independent growth and development of additional cancer relevant 
phenotypes including the role of AURKA in maintaining stemness, as reported 
by Lee et al in 2012 [75] will be extremely important in designing effective 
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therapeutic strategies for AURKA and UBE2C over expressing subset of 
human cancers. 
      Crosstalk between the AURKA pathway and important oncogenic 
signaling pathways including Wnt/β-catenin has been reported in multiple 
myeloma, MYC in neuroblastoma and BMI1 in head and neck cancer [40, 76, 
77]. It is likely that interaction between AURKA and UBE2C facilitates and 
may even prove to be vital for the activation of other such oncogenic 
pathways. An overview of the changes in expression of well-characterized 
oncogenes and oncoproteins could be assessed by microarray analysis and 
Reverse Phase Protein Array analysis of the cells overexpressing AURKA 
and UBE2C as compared to cells with low AURKA expression. Integrating this 
data may provide important leads on potential signaling pathways being 
affected by the interaction between AURKA and UBE2C. 
      Although we have observed mutual co-occurrence of overexpression of 
AURKA and UBE2C in publicly available datasets at the mRNA level as well 
as in cell lines at the protein level, it is important to investigate the 
phenomenon in tumor tissues as well. IHC staining of the two proteins in CRC 
tissues would not only help validate our observations  in the cell lines but also 
shed light on the clinical significance of this signaling axis in disease 
prognosis and therapeutic response of  colorectal cancer patients. 
      Unlike AURKA which has been the focus of many clinical trials in 
hematologic as well as solid tumors, there is as yet no clinical trial targeting 
UBE2C, even though its potential as a therapeutic target has been previously 
discussed by Bavi et al [70]. This can be first attempted in a pre-clinical 
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setting in vitro, by treating cells with a combination of AURKA inhibitor like 
Alisertib and proteasome inhibitor like Bortezomib, shown to downregulate 
UBE2C, and observing the effects on cell proliferation, migration-invasion, cell 
death and chemoresistance, in comparison with these drugs as single agents. 
If the results are promising, subsequent pre-clinical in vivo studies with mouse 
xenograft models could be undertaken with patient tumors that overexpress 
both AURKA and UBE2C to investigate the effect of combination therapy on 
tumor response.    Ultimately, stratification of patients based on co-expression 
of AURKA and UBE2C could be developed as an important biomarker-based 
selection process for administering this combination therapy to patients in 
clinical settings. .  
  
 
 
42 
 
Online Links 
Link 1: 
http://www.cancer.org/acs/groups/content/@editorial/documents/document/ac
spc-044552.pdf  
Link 2: 
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/
acspc-042151.pdf  
Link 3: 
http://dharmacon.gelifesciences.com/uploadedfiles/resources/delta-cq-solaris-
technote.pdf 
Link 4: 
http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&position=chr20%3A44440170-
44446682&hgsid=429541681_dnRwkuwLu7Ajo61eCv1V3e2oynre  
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